What is Morphocell Technologies?
Based in Montreal, Morphocell Technologies operates at the intersection of biotechnology and advanced tissue engineering. Since its inception in 2018, the company has focused on the development of stem cell-derived tissue and organ replacement therapies. By leveraging a sophisticated iPSC-derived platform, Morphocell is building a robust pipeline of therapeutic solutions. The firm's primary clinical focus is currently directed toward liver disease, a condition that represents a significant unmet medical need globally. By integrating scientific rigor with scalable manufacturing processes, the company is positioning itself as a leader in the next generation of regenerative medicine, aiming to provide durable, life-saving alternatives to traditional organ transplantation.
How much funding has Morphocell Technologies raised?
Morphocell Technologies has raised a total of $50M across 1 funding round:
Series A
$50M
Series A (2025): $50M with participation from CDP Venture Capital SGR and Investissement Quebec
Key Investors in Morphocell Technologies
CDP Venture Capital SGR
A prominent European venture capital fund manager that focuses on strategic investments in high-growth sectors, including digital health and sustainable innovation.
Investissement Quebec
A government-backed investment corporation dedicated to fostering economic growth and job creation in Quebec through strategic equity and loan financing.
What's next for Morphocell Technologies?
With this recent capital, Morphocell Technologies is well-positioned to accelerate its clinical development programs and expand its manufacturing capabilities. The strategic focus will likely shift toward advancing its lead liver disease candidate through critical regulatory milestones and clinical trials. As the company scales, it will need to navigate the complex landscape of regenerative medicine, balancing technical innovation with the stringent requirements of global health authorities. The backing from institutional investors suggests a long-term commitment to building a sustainable, high-impact biotechnology enterprise capable of delivering transformative therapies to the global market.
See full Morphocell Technologies company page
